Möchten Sie immer auf dem neuesten Stand bleiben?

Exton, PA, July 08, 2026 (GLOBE NEWSWIRE) -- The European market for metabolic dysfunction-associated steatohepatitis (MASH) is entering a pivotal phase of development as increasing disease...

Tekton Research, a multi-specialty clinical research site organization, is expanding its partnership with Summit Clinical Research Solutions (“Summit”).

GENFIT announced the coverage and future reimbursement by U.S. Medicare for NASHnext®, a non invasive blood test available through Labcorp

Couverture et futur remboursement sécurisés pour NASHnext®, le test diagnostique sanguin non invasif développé par Labcorp, basé sur la technologie propriétaire NIS4® de GENFITUn ciblage sur les...

Access to Labcorp’s NASHnext® is now available through Labcorp OnDemand

Labcorp OnDemand facilite l’accès au test NASHnext® dans le cadre d’un parcours de soins piloté par un médecin, pour identifier les patients atteints de MASH « à risque » Cette plateforme élargit...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel...

Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASH Rezdiffra improved atherogenic lipid profiles...

Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra® (resmetirom)Analysis of two-year data in...

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide